Shares of Cortexyme Inc. CRTX, -7.43% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment failed to meet the study's endpoints. Cortexyme's stock is down 43.3% this year; the S&P 500 SPX, +0.19% is up 21.8%.
20% of life is what happens to you and 80% is how you react to what happens to you...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.